Literature DB >> 15249632

Clonal evolution as pathogenetic mechanism in relapse of primary CNS lymphoma.

H Pels1, M Montesinos-Rongen, C Schaller, D Van Roost, U Schlegel, O D Wiestler, M Deckert.   

Abstract

Comparative investigation of immunoglobulin (Ig) heavy chain gene rearrangements and DNA sequence analyses of a primary lymphoma of the CNS (PCNSL) and its recurrence revealed that both tumors used the same Ig gene segment. In addition to shared somatic mutations, the primary and the recurrent PCNSLs harbored somatic mutations unique to each tumor. Clonal evolution rather than subclone selection appears to underlie the development of tumor recurrence in this case.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15249632     DOI: 10.1212/01.wnl.0000132649.24618.8a

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  4 in total

Review 1.  Neuro-oncology in a nutshell.

Authors:  Joachim M Baehring
Journal:  J Neurooncol       Date:  2004-11       Impact factor: 4.130

2.  Late relapse in primary central nervous system lymphoma: clonal persistence.

Authors:  Lakshmi Nayak; Cyrus Hedvat; Marc K Rosenblum; Lauren E Abrey; Lisa M DeAngelis
Journal:  Neuro Oncol       Date:  2011-03-03       Impact factor: 12.300

3.  Patterns of relapse in primary central nervous system lymphoma: inferences regarding the role of the neuro-vascular unit and monoclonal antibodies in treating occult CNS disease.

Authors:  Prakash Ambady; Rongwei Fu; Joao Prola Netto; Cymon Kersch; Jenny Firkins; Nancy D Doolittle; Edward A Neuwelt
Journal:  Fluids Barriers CNS       Date:  2017-06-02

4.  Twenty-year follow-up of a pilot/phase II trial on the Bonn protocol for primary CNS lymphoma.

Authors:  Sabine Seidel; Hendrik Pels; Sabine Schlömer; Annika Kowoll; Klaus Fliessbach; Andreas Engert; Marlies Vogt-Schaden; Gerlinde Egerer; Heinz Reichmann; Gabriele Schackert; Frank Kroschinsky; Martina Deckert; Ulrich Herrlinger; Thomas Klockgether; Rolf Fimmers; Udo Bode; Ingo G H Schmidt-Wolf; Uwe Schlegel
Journal:  Neurology       Date:  2020-09-28       Impact factor: 9.910

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.